Found 14 matching trials
Bisphosphonate Therapy in MONA Spectrum Disorder N/A Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder...
Show More Location
Multiple Locations
Learn More & Join Trial
CHronic Nonbacterial Osteomyelitis International Registry N/A The objective of the study is to establish a prospective disease registry f...
Show More Location
Seattle Children's Hospital
Learn More & Join Trial
The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer PHASE4 Metastatic breast cancer patients with bone involvement who are at high-ris...
Show More Location
The Ottawa Hospital Cancer Centre
Learn More & Join Trial
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain PHASE1 RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodiu...
Show More Learn More & Join Trial
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma PHASE3 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cel...
Show More Location
CCOP - Scottsdale Oncology Program
Learn More & Join Trial
Atorvastatin (Lipitor) to Prevent Bone Pain NA In the proposed randomized double blind cross-over placebo controlled study...
Show More Location
Children's Mercy Hospital
Learn More & Join Trial
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates PHASE2 The purpose of this trial is to determine the effectiveness of AMG 162 in r...
Show More Location
Multiple Locations
Learn More & Join Trial
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade PHASE2 The purpose of this study is to study the MRD status after VELCADE based in...
Show More Location
University of Tennessee Cancer Institute, Boston Baskin Cancer Group
Learn More & Join Trial
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer PHASE4 The investigators propose to perform a pragmatic, multicenter, open-label, ...
Show More Status
Active Not Recruiting
Location
William Osler Health System
Learn More & Join Trial
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases PHASE4 The current Rethinking Clinical Trials (REaCT) trial will compare two sched...
Show More Location
The Ottawa Hospital Research Institute
Learn More & Join Trial